Bluebird bio, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (66)

Latest Posts

About This Stock More About This Stock
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
Biopharma Stocks Rally And Gene Therapy Stocks Are Still Hot
Article By: Rod Raynovich
Friday, March 22, 2019 7:17 AM EDT
Mid-Cap biotech stocks ran up today along with a broad market rally in tech stocks with the NAZ up 1.42% and the XLK​ up 2.51%.
In this article: NAZ, RHHBY, BLUE, BIIB, XLK, ACIU
Read
Small Cap Biotechs Lead The Market In 2019 Up 20% YTD
Article By: Rod Raynovich
Thursday, February 28, 2019 12:20 PM EDT
Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%.
In this article: ONCE, RARE, DHR, GE, XBI, BLUE, CRSP, IWM, XLV, MRK, RHHBY, BMY, CELG, LOXO, LLY, GNMK, AMRN, TDOC
Read
5 Best Biotech Bets Likely To Outperform Estimates In Q4
Article By: Zacks Investment Research
Wednesday, January 23, 2019 2:06 PM EDT
There are multiple drug/biotech companies poised to beat on fourth-quarter earnings.
In this article: CELG, REGN, AMGN, ALNY, BLUE Also: BMY, LLY, LOXO
Read
Q2 Earnings Update: Bluebird Bio (BLUE) And Regeneron (REGN)
Article By: Rod Raynovich
Thursday, August 2, 2018 11:09 PM EDT
Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. Bluebird Bio (BLUE) was up 0.79% to $156.60 despite losses and lagging revenue.
In this article: BLUE, REGN
Read

PARTNER HEADLINES

Latest Tweets for $BLUE

No tweets yet!